Darolutamide/ADT Combo Delays Disease Worsening in Some PC, Phase 3 Trial Shows

Darolutamide/ADT Combo Delays Disease Worsening in Some PC, Phase 3 Trial Shows
Darolutamide in combination with androgen deprivation therapy (ADT) delays disease worsening in men with non-metastatic castration-resistant prostate cancer (nmCRPC) and stabilizes their quality of life without increasing the incidence of adverse events, new data from a Phase 3 trial shows. The findings were presented in an oral presentation titled, "Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC)," at the recent 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Darolutamide, also known as ODM-201 or BAY-1841788, is an investigational prostate cancer therapy being developed by Bayer and Orion. It is an androgen receptor antagonist that binds to the receptor, interrupting the androgen signaling cascade and preventing cancer cells from receiving growth signals. The safety and efficacy of darolutamide among patients with nmCRPC is being tested in a multi-center, randomized, double-blind, placebo-controlled, Phase 3 trial (NCT02200614), called ARAMIS. The study enrolled 1,509 patients wh
Subscribe or to access all post and page content.